Trending NewsTrending NewsNASDAQ:GLSI Greenwich LifeSciences (GLSI) Stock Price, News & Analysis $12.18 +0.33 (+2.78%) Closing price 04:00 PM EasternExtended Trading$12.15 -0.03 (-0.25%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Greenwich LifeSciences Stock (NASDAQ:GLSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Greenwich LifeSciences alerts:Sign Up Key Stats Today's Range$11.92▼$12.3350-Day Range$8.76▼$12.4952-Week Range$8.06▼$16.50Volume37,473 shsAverage Volume58,114 shsMarket Capitalization$166.01 millionP/E RatioN/ADividend YieldN/APrice Target$42.00Consensus RatingBuy Company Overview Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Read More Greenwich LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreGLSI MarketRank™: Greenwich LifeSciences scored higher than 29% of companies evaluated by MarketBeat, and ranked 821st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGreenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGreenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.Read more about Greenwich LifeSciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Greenwich LifeSciences are expected to decrease in the coming year, from ($0.80) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Greenwich LifeSciences is -8.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Greenwich LifeSciences is -8.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGreenwich LifeSciences has a P/B Ratio of 110.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.36% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 4.00%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGreenwich LifeSciences does not currently pay a dividend.Dividend GrowthGreenwich LifeSciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.36% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 4.00%, indicating that investor sentiment is decreasing. News and Social Media1.9 / 5News Sentiment0.38 News SentimentGreenwich LifeSciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Greenwich LifeSciences this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for GLSI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Greenwich LifeSciences insiders have not sold or bought any company stock.Percentage Held by Insiders51.67% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.16% of the stock of Greenwich LifeSciences is held by institutions.Read more about Greenwich LifeSciences' insider trading history. Receive GLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address GLSI Stock News HeadlinesGreenwich LifeSciences (NASDAQ:GLSI) Coverage Initiated at Noble FinancialAugust 22 at 2:17 AM | americanbankingnews.comGreenwich LifeSciences initiated with an Outperform at Noble CapitalAugust 20 at 4:38 PM | msn.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 22 at 2:00 AM | Brownstone Research (Ad)Greenwich LifeSciences, Inc. Gains Coverage from Noble Capital Markets Amid Phase III Trial of GLSI-100 for Breast CancerAugust 20 at 9:31 AM | quiverquant.comQNoble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciencesAugust 20 at 9:25 AM | globenewswire.comGreenwich LifeSciences to build out internal clinical trial operations teamAugust 20 at 2:25 AM | msn.comGreenwich LifeSciences, Inc. Expands Internal Clinical Trial Management Team for FLAMINGO-01 Phase III StudyAugust 19 at 6:51 AM | quiverquant.comQGreenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations TeamAugust 19 at 6:00 AM | globenewswire.comSee More Headlines GLSI Stock Analysis - Frequently Asked Questions How have GLSI shares performed this year? Greenwich LifeSciences' stock was trading at $11.23 at the start of the year. Since then, GLSI shares have increased by 8.5% and is now trading at $12.18. How were Greenwich LifeSciences' earnings last quarter? Greenwich LifeSciences, Inc. (NASDAQ:GLSI) released its quarterly earnings data on Thursday, August, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.06. When did Greenwich LifeSciences IPO? Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital served as the underwriter for the IPO. Who are Greenwich LifeSciences' major shareholders? Greenwich LifeSciences' top institutional shareholders include Geode Capital Management LLC (1.04%), Marshall Wace LLP (0.42%) and Police & Firemen s Retirement System of New Jersey (0.02%). Insiders that own company stock include Snehal Patel and Jaye Thompson. View institutional ownership trends. How do I buy shares of Greenwich LifeSciences? Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Greenwich LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/14/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLSI CIK1799788 Webwww.greenwichlifesciences.com Phone832-819-3232FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for Greenwich LifeSciences$42.00 High Price Target$45.00 Low Price Target$39.00 Potential Upside/Downside+244.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-700.90% Return on Assets-455.64% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book110.73Miscellaneous Outstanding Shares13,630,000Free Float6,587,000Market Cap$166.01 million OptionableNot Optionable Beta1.65 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:GLSI) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.